by Mayo Clinic Laboratories
A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.
Language
🇺🇲
Publishing Since
4/20/2020
Email Addresses
1 available
Phone Numbers
0 available
April 24, 2025
<p>In this episode of “Answers From the Lab,” <a href="https://www.mayoclinic.org/biographies/morice-william-g-ii-m-d-ph-d/bio-20513146?_ga=2.106105411.1343509777.1655124262-1313760223.1621880990">William Morice II, M.D., Ph.D.</a>, CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of <a href="https://ampriondx.com/">Amprion</a>. They discuss their <a href="https://news.mayocliniclabs.com/2025/03/26/mayo-clinic-laboratories-and-amprion-announce-collaboration-to-advance-neurodegenerative-disease-diagnostics/">strategic collaboration</a> and the innovative SAAmplify™–αSYN (CSF) test. They covered: </p><ul><li>Details about how the cerebrospinal fluid biomarker test (<a href="https://news.mayocliniclabs.com/neurology/dementia/synucleinopathies/">Mayo ID: ASYNC</a>) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.</li><li>Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.</li><li>Information physicians receive from the test, and when they should consider ordering it for their patients. </li><li>Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN. </li></ul><p><br></p>
April 15, 2025
<p>Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' <a href="https://www.mayocliniclabs.com/test-catalog/overview/607691">SPAS</a> test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.</p><p><br>Speaker 3: (00:33)<br> Do you mind telling us a little bit about yourself and your background?</p><p> </p><p>Speaker 3: (01:45)<br>Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation?</p><p> </p><p>Speaker 3: (05:25)<br>Which patients should have this testing, and when should it be performed?</p><p> </p><p>Speaker 3: (06:57)<br>What alternative test options are available, and how does testing at Mayo Clinic compare?</p><p> </p><p>Speaker 3: (08:37)</p><p>How are the results used in patient care?</p>
April 10, 2025
<p>In this episode of “Answers From the Lab,” host <a href="https://www.mayoclinic.org/biographies/pritt-bobbi-s-m-d/bio-20514068?_ga=2.15311862.1343509777.1655124262-1313760223.1621880990">Bobbi Pritt, M.D., </a>chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by <a href="https://www.mayoclinic.org/biographies/morice-william-g-ii-m-d-ph-d/bio-20513146?_ga=2.106105411.1343509777.1655124262-1313760223.1621880990">William Morice II, M.D., Ph.D.</a>, CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT). They covered: <br> </p><ul><li>Details about the ruling to vacate the FDA’s rule on LDT oversight. </li><li>What LDT oversight might look like in the future. </li><li>How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation. </li></ul><p><br></p>
Mayo Clinic Laboratories
Mayo Clinic
Freakonomics Radio + Stitcher
Marketplace
JAMA Network
Freakonomics Network & Zachary Crockett
NPR
Ben Gilbert and David Rosenthal
The Wall Street Journal & Gimlet
Freakonomics Radio + Stitcher
STAT
JAMA Network
NPR
The Curious Clinicians
ARUP Laboratories
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.